Glycostem is a company specializing in allogeneic cellular immunotherapy. It uses allogeneic cells like Natural Killer (NK) cells for the treatment of leukemia, lymphoma, and solid tumors. The company also develops a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from umbilical cord blood.